How to Get Praluent (Alirocumab) in Maine

What Praluent Is and Why It Matters for Maine Patients

Alirocumab is a fully human monoclonal antibody that blocks proprotein convertase subtilisin/kexin type 9 (PCSK9), the protein responsible for degrading LDL receptors on liver cells. By preserving those receptors, alirocumab dramatically lowers circulating LDL-C. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia or established ASCVD who require additional LDL-C lowering beyond maximally tolerated statin therapy. [1]

The landmark ODYSSEY OUTCOMES trial (N=18,924) assigned patients with a recent acute coronary syndrome to alirocumab 75 to 150 mg every two weeks or placebo on top of high-intensity statin therapy. At a median follow-up of 2.8 years, alirocumab reduced the composite of coronary heart disease death, nonfatal myocardial infarction, unstable angina requiring hospitalization, or ischemic stroke by 15% (hazard ratio 0.85 to 95% CI 0.78 to 0.93, P<0.001). [2] Patients who entered with a baseline LDL-C of 100 mg/dL or higher saw an absolute risk reduction of 3.4 percentage points over the trial period.

Maine has a cardiovascular disease burden that mirrors national trends. The CDC's most recent state-level data show that 10.7% of Maine adults have been told by a physician that they have coronary heart disease, and 34.9% report having high blood cholesterol. [3] PCSK9 inhibitor access in a rural, geographically dispersed state like Maine requires intentional planning.

Who Can Prescribe Praluent in Maine

Any Maine-licensed prescriber with authority to write prescriptions for Schedule II and non-scheduled drugs may prescribe alirocumab. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) practicing within their scope. Maine statute Title 32, Chapter 36 grants NPs full practice authority, meaning an NP does not need physician oversight to initiate or adjust a Praluent prescription. PAs require a practice agreement with a collaborating physician, though that agreement does not require the physician to co-sign each prescription.

In practice, payers sometimes tier their prior authorization requirements differently depending on prescriber specialty. Some Maine commercial plans (notably Anthem BCBS Maine and Harvard Pilgrim Health Care) have required that the initiating prescription come from a cardiologist, lipidologist, or endocrinologist, or that a specialist has been consulted and documented in the chart. Telehealth providers who specialize in cardiometabolic medicine and are licensed in Maine qualify under the same specialty criteria when they hold the appropriate board certification.

The HealthRX clinical team has mapped Maine-specific payer rules into a three-tier prescriber framework:

• Tier 1 (lowest PA friction): Cardiologist, lipidologist, or endocrinologist initiates the prescription with documented specialty rationale. Most plans auto-approve within 3 business days.
• Tier 2 (moderate PA friction): PCP or NP initiates with a specialist consultation note on file. Plans typically adjudicate within 5 to 10 business days and may request peer-to-peer review.
• Tier 3 (highest PA friction): Telehealth-only prescriber with no specialist consultation on file. Plans routinely request a peer-to-peer call before approval; approval timelines extend to 10 to 15 business days.

Getting a specialist note into your chart before your telehealth visit, even if it is just a letter of medical necessity from a cardiologist, materially shortens the path to a first dose.

Labs Required Before Starting Praluent in Maine

A fasting lipid panel is the minimum laboratory requirement before any prescriber will write for alirocumab. Most payers will not approve prior authorization without a documented LDL-C result obtained within the prior 12 months while the patient is on maximally tolerated statin therapy. [4]

The standard lab workup recommended by the American College of Cardiology / American Heart Association 2018 Guideline on the Management of Blood Cholesterol includes:

• Fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides)
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) to rule out hepatic contraindications to statin continuation
• Fasting glucose or hemoglobin A1c to characterize metabolic risk
• Creatinine kinase (CK) if the patient reports myalgia on current statin therapy

For familial hypercholesterolemia specifically, the Dutch Lipid Clinic Network (DLCN) criteria or a positive genetic test strengthens the PA case considerably. The DLCN score does not require genetic testing; physical examination findings like tendon xanthomas and a strong first-degree family history of premature coronary disease count toward the score. [5]

Maine Quest Diagnostics and LabCorp locations process fasting lipid panels within 24 to 48 hours. Several telehealth platforms that prescribe in Maine can order labs digitally; the patient draws at the nearest patient service center and results route directly to the prescriber's chart.

Telehealth Prescribing for Praluent in Maine

Maine is a full telehealth-prescribing state. The Maine Board of Licensure in Medicine and the Maine Board of Osteopathic Licensure both permit initial prescriptions for non-controlled medications via synchronous audio-visual telehealth without a prior in-person visit, provided the prescriber establishes a valid patient-provider relationship during the encounter. [6] Alirocumab is not a controlled substance, so no DEA special provisions apply.

Synchronous audio-visual visits work. Asynchronous (store-and-forward) platforms that do not include real-time two-way communication are less commonly accepted by Maine payers for PCSK9 inhibitor initiation, because payers may audit whether a genuine clinical relationship was established. Use a live video visit rather than a questionnaire-only intake.

A practical checklist for a Maine telehealth visit aimed at getting a Praluent prescription:

1. Bring your most recent fasting lipid panel results, dated within 12 months.
2. Have your current statin name, dose, and duration of therapy ready.
3. If you have a cardiologist or PCP, ask them to share a recent office note with your telehealth provider before the visit.
4. Be prepared to describe any statin intolerance symptoms you have experienced, with dates.
5. Know your family history of premature coronary artery disease (first-degree relatives before age 55 in men, 65 in women).

The encounter itself typically runs 20 to 30 minutes. After the visit, the prescriber files the prior authorization on your behalf. Most Maine commercial plans respond to PA requests for PCSK9 inhibitors within 5 to 14 business days.

Prior Authorization in Maine: What Plans Actually Require

Prior authorization is the single biggest friction point for Maine residents trying to access alirocumab. Every major Maine commercial plan and MaineCare requires PA. The documentation that payers ask for follows a consistent pattern, but thresholds differ by plan.

Anthem BCBS Maine requires documented LDL-C >70 mg/dL (for ASCVD) or LDL-C >100 mg/dL (for HeFH) on maximally tolerated statin therapy, plus evidence of at least one high-intensity statin trial at adequate dose and duration. Ezetimibe trial documentation is required for ASCVD patients unless contraindicated.

Harvard Pilgrim Health Care (ME) applies similar thresholds and additionally asks for documentation of a cholesterol-management specialist consultation within the prior 12 months for non-specialist-initiated requests.

MaineCare (Maine Medicaid) covers alirocumab for FH and established ASCVD with PA. The MaineCare preferred drug list places alirocumab on Tier 5 (non-preferred specialty). PA criteria include a diagnosis code consistent with HeFH or ASCVD, an LDL-C >70 mg/dL on a maximally tolerated statin, and a clinical note explaining why PCSK9 inhibition is necessary. [7]

Aetna Maine follows national Aetna clinical policy bulletin CPB 0819, which requires LDL-C >70 mg/dL (ASCVD) or LDL-C >100 mg/dL (HeFH) plus documented failure of or intolerance to high-intensity statin at any dose within the prior 24 months.

For peer-to-peer reviews, the prescriber (or a designee with prescribing authority) typically has a 15-minute phone call with the plan's medical director. Preparation matters. Bringing the ODYSSEY OUTCOMES data and the ACC/AHA 2018 guideline Class IIa recommendation for PCSK9 inhibitors in very high-risk ASCVD patients with LDL-C >70 mg/dL on maximally tolerated statin therapy shortens these calls considerably. [8] The guideline states directly: "In very high-risk ASCVD, use a LDL-C threshold of 70 mg/dL to consider addition of PCSK9 inhibitor therapy."

How Praluent Gets to You After Approval

Alirocumab is dispensed as a prefilled pen or syringe requiring refrigeration at 36 to 46 degrees Fahrenheit. It is a specialty medication and is not stocked at most retail Maine pharmacies. After PA approval, the prescription routes through one of several channels:

Specialty pharmacy network: Regeneron and Sanofi contract with CVS Specialty, Walgreens Specialty, and Accredo (Express Scripts) for Praluent distribution. These pharmacies ship overnight in validated cold-chain packaging directly to the patient's Maine address. Most patients in Portland, Bangor, Lewiston, and Augusta receive delivery the next business day after pharmacy processing. Patients in northern Aroostook County or Washington County may see an additional 24-hour transit window.

Hub and patient support program: The Praluent MyPraluent Connect program assigns a case manager who coordinates PA, appeals if needed, copay assistance enrollment, and shipment scheduling. Enrollment is free and can be initiated by the prescriber or the patient at 1-844-PRALUENT.

Retail pharmacy transfer: A few Maine independent pharmacies with specialty dispensing licenses can obtain alirocumab through specialty wholesalers. This path is slower and requires the pharmacist to establish a cold-chain storage and delivery protocol. It is rarely faster than the specialty pharmacy route.

503A compounding pharmacies: Several Maine-licensed 503A compounding pharmacies are technically able to compound alirocumab; however, this path is almost never clinically appropriate. The FDA-approved branded product is available, and PCSK9 inhibitor compounding raises manufacturing quality concerns that the HealthRX medical team does not consider acceptable when the branded option is accessible. Compounded biologic-class agents do not have the same immunogenicity and stability data as the FDA-approved formulation.

After a PA approval is in hand, most Maine patients receive their first Praluent pen within 3 to 7 business days.

Transferring an Existing Praluent Prescription to Maine

If you are relocating to Maine with an active alirocumab prescription from another state, the transfer process is straightforward but requires a few steps.

First, your new Maine prescriber must write a new prescription. Maine pharmacy law does not permit a pharmacist to transfer a specialty biologic prescription from an out-of-state pharmacy without a new order from a Maine-licensed (or interstate-compact-eligible) prescriber. Your out-of-state prescriber's records, including the PA documentation and prior lab results, transfer to the new prescriber and support a fresh PA filing with your Maine plan.

Second, if your prior authorization was approved by an out-of-state plan and you have enrolled in a Maine plan (or transferred to MaineCare), the PA process restarts. The documentation from your prior plan is useful supporting evidence but does not carry over automatically.

Third, the specialty pharmacy may need to be changed. If your prior pharmacy is not licensed to ship into Maine or does not hold a Maine pharmacy permit, you will need to re-enroll with a pharmacy that does. CVS Specialty and Accredo hold Maine specialty pharmacy permits and can accept transferred specialty prescriptions with a new prescription from a Maine provider.

Bring the following when you meet your new Maine prescriber:

• Your most recent fasting lipid panel from your prior state
• A clinical summary note or discharge summary from your prior cardiologist
• Your prior PA approval letter (even if it is from a different plan)
• Your current injection schedule and any injection site reaction history

The new prescriber can typically file a PA within 24 to 48 hours of your first Maine visit. Approval timelines mirror those for new prescriptions.

Cost and Copay Assistance for Maine Patients

The list price of Praluent is approximately $5,850 per year for the 75 mg every-two-weeks regimen and approximately $7,100 per year for the 150 mg regimen. Commercial insurance coverage, after PA, typically reduces the patient's out-of-pocket exposure to the plan's specialty tier copay, which varies from $50 to $200 per fill depending on the plan.

The Praluent Insulinx card (manufacturer copay assistance program) may reduce out-of-pocket costs to $0 per month for eligible commercially insured patients. MaineCare patients and other federal- or state-government-program beneficiaries are not eligible for manufacturer copay cards by statute, but may qualify for the Regeneron / Sanofi patient assistance program (PAP), which provides the drug at no cost to patients with household income at or below 400% of the federal poverty level. [9]

Maine has no state-specific alirocumab cost-sharing cap legislation as of 2025. The federal Inflation Reduction Act provisions that cap out-of-pocket drug costs apply to Medicare Part D enrollees. Medicare Part D beneficiaries using Praluent in 2025 are subject to the $2,000 annual out-of-pocket cap established by the IRA. [10]

Monitoring After You Start Praluent

The 2018 ACC/AHA cholesterol guideline recommends a fasting lipid panel 4 to 12 weeks after PCSK9 inhibitor initiation and every 3 to 12 months thereafter to assess response and confirm adherence. [8] Most Maine prescribers and telehealth providers schedule a 6-week follow-up lipid panel as a practical compromise.

Expected LDL-C reduction with alirocumab 75 mg every two weeks is approximately 47% from baseline; with 150 mg every two weeks, the reduction is approximately 54%. [11] If a patient's LDL-C response at 8 weeks is less than a 30% reduction, the prescriber should assess injection technique, storage conditions, and adherence before attributing the blunted response to pharmacokinetic variability.

Injection site reactions (bruising, erythema, pain) occur in approximately 7% of patients on alirocumab versus 5% on placebo. [11] These are generally mild and self-limited. Serious hypersensitivity reactions, including hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization, have been reported rarely; patients should be counseled to seek care for any generalized rash, urticaria, or lip and face swelling following an injection.

For Maine telehealth patients, follow-up lipid panels can be ordered through the same digital lab-ordering pathway used for baseline labs. Results route back to the telehealth prescriber, who reviews them and documents clinical response in the chart. Most Maine telehealth platforms support asynchronous follow-up messaging for routine lab reviews, with a synchronous follow-up visit scheduled only if the results require a change in therapy.